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In autumn 2014, with great effort by the Ministry of Health, Labour and Welfare, the research group will obtain
several vials of redback spider (RBS) antivenom for emergency use. However, these small amounts of antivenom are
insufficient to cover the demands from majority of hospitals in Japan. The research group carefully discussed the
domestic RBS antivenom production by themselves for this emergency. We have now entered the second stage for
large-scale antivenom production. Although the domestic production of RBS antivenom has started, great caution
is required as we move forward with this plan.
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We previously reported that symptoms of redback spider
(RBS) bites are usually mild and localized, such as local
pain and erythema [1]. However, fatal cases had been re-
ported before the development of antivenom, which is
manufactured by the immunization of horses [2,3].
RBSs were found in Metropolitan Tokyo on September
25, 2014, and they are rapidly becoming a nationwide
problem in Japan [4]. The definitive treatment for RBS
envenomation is to use the specific RBS antivenom pro-
duced by the Commonwealth Serum Laboratories (CSL)
in Australia. However, a serious issue with the current
practice is that RBS antivenom is used as an off-label
drug in Japan and must be privately imported from
Australia [1].
To compound this issue, RBS antivenom imports from
CSL were suspended in autumn 2013. The Ministry of
Health, Labour and Welfare (MHLW) launched a re-
search group to evaluate the safety and efficacy of the
antivenom and to organize and maintain information on
RBS bites from April 2013 [1]. In autumn 2014, with
great effort by MHLW, the research group will obtain
several vials of antivenom for emergency use. However,* Correspondence: hifumitoru@gmail.com
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cover the demands from majority of hospitals in Japan.
The research group carefully discussed the option
for domestic RBS antivenom production by themselves
for this emergency. The first stage started in April
2014. Over 5,000 RBSs were collected, and their
venom was extracted by research group in the summer
of 2014. We have now entered the second stage of de-
velopment to evaluate the potency for large-scale anti-
venom production.
We foresee many difficulties in this process. First, be-
cause supplemental details of current RBS antivenom
production were not obtained, we have had to refer to a
method described over 60 years ago [5]. Second, not
many horses were immunized due to the limited grant
fund, raising the possibility that we will be unable to ob-
tain enough antivenom, especially if the horses die.
Third, because this is the first time we have attempted
to produce RBS antivenom, unexpected problems may
occur.
In conclusion, although the domestic production of
RBS antivenom has started, great caution is required as
we move forward with this plan.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TH, HT, AY, MA, YKoido, and YKuroda participated in the current research
project. TH wrote the manuscript. HT, AY, MA, and YK revised and edited the
manuscript. All authors read and approved the final manuscript.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hifumi et al. Journal of Intensive Care  (2015) 3:7 Page 2 of 2Acknowledgements
This study was supported by the Health Science Grants (2013–2015) from
the Ministry of Health, Labour and Welfare of Japan.
Author details
1Emergency Medical Center, Kagawa University Hospital, 1750-1 Ikenobe,
Miki, Kita, Kagawa 761-0793, Japan. 2Ministry of Health, Labour and Welfare,
1-2-2 Kasumigaseki Chiyoda-ku, Tokyo 100-8916, Japan. 3Department of
Bacteriology II, National Institute of Infectious Disease, Gakuen 4-7-1,
Musashimurayama-shi, Tokyo 208-0011, Japan. 4Department of Immunology,
National Institute of Infectious Disease, Toyama 1-23-1, Shinjuku-ku, Tokyo
162-8640, Japan. 5Division of Critical Care Medicine and Trauma, National
Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa,
Tokyo 190-0014, Japan.
Received: 30 October 2014 Accepted: 29 December 2014
References
1. Hifumi T, Fujimi S, Yamagishi T, Arai S, Sawabe K, Yamamoto A, et al. Clinical
characteristics of redback spider bites. J Intensive Care. 2014;2.
2. Sutherland SK. Australian animal toxins. Melbourne: Oxford University
Press; 1983.
3. Braitberg G, Segal L. Spider bites—assessment and management. Aust Fam
Physician. 2009;38:862–7.
4. Japan ‘not ready’ for invasion of redbacks as venomous Australian spiders
reach Tokyo [http://www.abc.net.au/news/2014-10-20/redback-spiders-
found-for-the-first-time-in-tokyo/5827612]
5. Wiener S. The Australian red back spider (Latrodectus hasseltii). II. Effect of
temperature on the toxicity of venom. Med J Aust. 1956;43:331–4.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
